Eikon Therapeutics, Inc.'s (NASDAQ:EIKN) Lock-Up Period Will Expire on August 4th

Key Points

• Eikon Therapeutics’ IPO lock-up period expires August 4, allowing major shareholders and insiders to sell shares. The company issued 21.18 million IPO shares at $18 each, raising approximately $381.2 million.
• Analyst sentiment is mixed: five analysts rate the stock Buy, one rates it Hold, and two rate it Sell. MarketBeat reports a consensus rating of Hold with an average price target of $25.20.
• EIKN opened at $9.88, with a market capitalization of approximately $534.9 million and a 12-month trading range of $7.90 to $17.40. The company reported a quarterly loss of $26.23 per share.

Eikon Therapeutics' (NASDAQ:EIKN - Get Free Report) lock-up period will end on Tuesday, August 4th. Eikon Therapeutics had issued 21,177,600 shares in its IPO on February 5th. The total size of the offering was $381,196,800 based on an initial share price of $18.00. Shares of the company owned by major shareholders and company insiders will be eligible for trade following the end of the lock-up period.

Wall Street Analyst Weigh In

EIKN has been the topic of a number of research analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Eikon Therapeutics in a report on Tuesday, June 2nd. Weiss Ratings began coverage on Eikon Therapeutics in a report on Monday, June 1st. They issued a "sell (e-)" rating for the company. Wall Street Zen downgraded Eikon Therapeutics from a "hold" rating to a "sell" rating in a report on Sunday, April 5th. Finally, Wedbush decreased their target price on Eikon Therapeutics from $7.00 to $5.00 and set an "underperform" rating for the company in a research report on Tuesday, May 12th. Five analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $25.20.

Eikon Therapeutics Stock Up 11.0%

Shares of EIKN stock opened at $9.88 on Tuesday. The stock has a 50 day moving average of $10.24. The stock has a market capitalization of $534.89 million and a PE ratio of -4.02. Eikon Therapeutics has a 12-month low of $7.90 and a 12-month high of $17.40.

Eikon Therapeutics (NASDAQ:EIKN - Get Free Report) last released its quarterly earnings results on Monday, March 30th. The company reported ($26.23) earnings per share (EPS) for the quarter.

Eikon Therapeutics Company Profile

We are a late-stage clinical biopharmaceutical company dedicated to building a global, fully-integrated organization developing important, innovative medicines to address serious unmet medical needs. We are led by world-renowned drug developers Dr. Roger M. Perlmutter, M.D., Ph.D., and Dr. Roy Baynes, M.D., Ph.D. Our vision is to become a generational leader, by purposefully integrating traditional biology research with advanced engineering to develop better medicines faster. Our initial focus is oncology, where we are advancing a pipeline of drug candidates targeting areas of high unmet need in large indications.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.